GSK gains 1st US OK for adjuvanted H5N1 vaccine
This article was originally published in Scrip
Executive Summary
In giving its blessing on 22 November to GlaxoSmithKline's vaccine to protect against the H5N1 avian influenza virus, known unofficially as Q-Pan, the FDA also granted its first approval to an adjuvanted pandemic flu vaccine, making that action an historical move, noted US Assistant Secretary for Preparedness and Response Dr Nicole Lurie.